RepliCel Begin Period Cash Flow vs Other Non Cash Items Analysis
RP Stock | CAD 0.01 0.00 0.00% |
RepliCel Life financial indicator trend analysis is much more than just breaking down RepliCel Life Sciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether RepliCel Life Sciences is a good investment. Please check the relationship between RepliCel Life Begin Period Cash Flow and its Other Non Cash Items accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Begin Period Cash Flow vs Other Non Cash Items
Begin Period Cash Flow vs Other Non Cash Items Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of RepliCel Life Sciences Begin Period Cash Flow account and Other Non Cash Items. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between RepliCel Life's Begin Period Cash Flow and Other Non Cash Items is -0.02. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Other Non Cash Items in the same time period over historical financial statements of RepliCel Life Sciences, assuming nothing else is changed. The correlation between historical values of RepliCel Life's Begin Period Cash Flow and Other Non Cash Items is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of RepliCel Life Sciences are associated (or correlated) with its Other Non Cash Items. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Non Cash Items has no effect on the direction of Begin Period Cash Flow i.e., RepliCel Life's Begin Period Cash Flow and Other Non Cash Items go up and down completely randomly.
Correlation Coefficient | -0.02 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Other Non Cash Items
Most indicators from RepliCel Life's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into RepliCel Life Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in RepliCel Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. At this time, RepliCel Life's Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to climb to 5.46 in 2024, whereas Enterprise Value Over EBITDA is likely to drop (3.54) in 2024.
RepliCel Life fundamental ratios Correlations
Click cells to compare fundamentals
RepliCel Life Account Relationship Matchups
High Positive Relationship
High Negative Relationship
RepliCel Life fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 505.5K | 421.0K | 591.8K | 798.2K | 287.8K | 273.4K | |
Total Current Liabilities | 1.6M | 2.2M | 1.7M | 2.1M | 1.8M | 1.9M | |
Total Stockholder Equity | (4.4M) | (5.1M) | (6.8M) | (5.9M) | (4.5M) | (4.3M) | |
Property Plant And Equipment Net | 6.0K | 4.4K | 3.3K | 2.4K | 967.0 | 918.65 | |
Net Debt | 425.4K | 41.7K | (186.9K) | (372.1K) | 754.0K | 791.7K | |
Retained Earnings | (36.6M) | (38.2M) | (42.2M) | (43.0M) | (43.3M) | (41.1M) | |
Accounts Payable | 640.3K | 1.3M | 602.0K | 817.9K | 416.0K | 472.3K | |
Cash | 23.9K | 34.4K | 221.2K | 413.0K | 59.2K | 56.2K | |
Non Current Assets Total | 272.2K | 235.3K | 198.8K | 162.5K | 125.7K | 119.4K | |
Cash And Short Term Investments | 52.7K | 51.6K | 238.4K | 430.3K | 76.4K | 72.6K | |
Net Receivables | 51.9K | 63.6K | 61.2K | 82.2K | 38.0K | 39.0K | |
Common Stock Shares Outstanding | 24.1M | 27.0M | 32.5M | 37.8M | 59.2M | 62.2M | |
Liabilities And Stockholders Equity | 505.5K | 421.0K | 591.8K | 798.2K | 287.8K | 273.4K | |
Other Stockholder Equity | 4.6M | 4.6M | 5.1M | 5.4M | 5.6M | 5.6M | |
Total Liab | 4.9M | 5.5M | 7.4M | 6.7M | 4.8M | 5.1M | |
Total Current Assets | 233.2K | 185.7K | 393.0K | 635.7K | 162.1K | 154.0K | |
Short Term Debt | 449.3K | 47.3K | 611.4K | 689.3K | 813.2K | 853.8K | |
Common Stock | 27.5M | 28.5M | 30.3M | 31.7M | 33.1M | 20.0M | |
Other Current Liab | 107.3K | 517.8K | 106.6K | 211.8K | 239.5K | 432.0K | |
Other Assets | 266.2K | 230.8K | 195.5K | 1.0 | 1.15 | 1.09 | |
Non Current Liabilities Total | 3.4M | 3.2M | 5.8M | 4.6M | 3.0M | 2.1M | |
Other Current Assets | 128.7K | 70.5K | 93.4K | 123.2K | 47.7K | 89.2K | |
Net Tangible Assets | (1.9M) | (4.4M) | (5.1M) | (6.8M) | (6.2M) | (5.9M) | |
Property Plant Equipment | 8.2K | 6.0K | 4.4K | 3.3K | 2.9K | 2.8K | |
Net Invested Capital | (2.9M) | (5.0M) | (6.8M) | (5.9M) | (5.3M) | (5.6M) | |
Net Working Capital | (1.2M) | (2.1M) | (1.3M) | (1.4M) | (1.3M) | (1.4M) | |
Capital Stock | 29.0M | 28.5M | 30.3M | 31.7M | 36.4M | 32.6M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for RepliCel Stock Analysis
When running RepliCel Life's price analysis, check to measure RepliCel Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RepliCel Life is operating at the current time. Most of RepliCel Life's value examination focuses on studying past and present price action to predict the probability of RepliCel Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RepliCel Life's price. Additionally, you may evaluate how the addition of RepliCel Life to your portfolios can decrease your overall portfolio volatility.